3.69
+0.08(+2.22%)
Currency In USD
| Previous Close | 3.61 |
| Open | 3.62 |
| Day High | 3.78 |
| Day Low | 3.58 |
| 52-Week High | 16.55 |
| 52-Week Low | 1.6 |
| Volume | 653,779 |
| Average Volume | 1.18M |
| Market Cap | 274M |
| PE | -2.69 |
| EPS | -1.37 |
| Moving Average 50 Days | 3.75 |
| Moving Average 200 Days | 3.77 |
| Change | 0.08 |
If you invested $1000 in Perspective Therapeutics, Inc. (CATX) 10 years ago, it would be worth $244.37 as of August 18, 2025 at a share price of $3.69. Whereas If you bought $1000 worth of Perspective Therapeutics, Inc. (CATX) shares 5 years ago, it would be worth $493.32 as of August 18, 2025 at a share price of $3.69.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
GlobeNewswire Inc.
Jul 24, 2025 4:45 PM GMT
SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that upd
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Jul 15, 2025 11:00 AM GMT
SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that it
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
GlobeNewswire Inc.
Jun 21, 2025 12:00 PM GMT
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2Dosimetry sub-study analysis presented at the Society of Nuclear Medicine &